1028 related articles for article (PubMed ID: 18981003)
1. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
3. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
8. [Indication of EGFR kinase inhibitors should be refined].
Heneberg P
Klin Onkol; 2011; 24(2):87-93. PubMed ID: 21644362
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
[TBL] [Abstract][Full Text] [Related]
10. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
12. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
17. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Pietanza MC; Lynch TJ; Lara PN; Cho J; Yanagihara RH; Vrindavanam N; Chowhan NM; Gadgeel SM; Pennell NA; Funke R; Mitchell B; Wakelee HA; Miller VA
J Thorac Oncol; 2012 Jan; 7(1):219-26. PubMed ID: 22011666
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Yoshimura N; Okishio K; Mitsuoka S; Kimura T; Kawaguchi T; Kobayashi M; Hirashima T; Daga H; Takeda K; Hirata K; Kudoh S
J Thorac Oncol; 2013 Jan; 8(1):96-101. PubMed ID: 23207920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
